ARS Pharmaceuticals shares rise on strong fourth-quarter allergy spray revenue By Investing.com

Investing.com — Shares of ARS Pharmaceuticals saw a significant rally, hitting a peak of 11%, marking its biggest intraday jump since August.

The jump was driven by the company’s announcement of preliminary net income for its Neffy allergy spray in the fourth quarter, which beat analysts’ forecasts.

Preliminary net product revenue for Neffy in the fourth quarter was approximately $6.5 million. The figure was well above the average estimate of $3.11 million projected by analysts, according to a Bloomberg survey.

In 2024, total net product sales were approximately $7.1 million. This revenue came after the anti-allergy spray became available to wholesalers and pharmacies on September 23.

Looking ahead to 2025, ARS Pharmaceuticals has indicated its intention to drive demand and gain greater traction among target prescribers.

This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.